论文部分内容阅读
为观察生物冶疗和生物化学治疗对恶性黑色素瘤病人术后存活的影响.取136例恶性黑色素瘤病人,男性80例,女性56例,中位年龄48岁(18岁～80岁).肿瘤部位以头面部和四肢最多见(占全部病例的69.9%),躯干,消化道和生殖系统分别占11.0%,8.1%和8.5%,较少见部位包括乳腺1例,子宫2例,食道3例,全组病人入院后分别接受手术及放疗,化疗,生物治疗和生物化学治疗,资料完整者111例,其中23例术后应用生物治疗(包括TAK细胞,IL-2和IFN-α);34例术后接受生物化学治疗(单药或多药化疗联合生物反应调节剂);48例术后应用放疗或化疗.化疗药物包括DDP(100mg/M2),CBP(350mg/M2),DTIC(125mg/M2×3)
To observe the effect of biotherapy and biochemotherapy on postoperative survival of malignant melanoma patients, 136 patients with malignant melanoma were enrolled, including 80 males and 56 females. The median age was 48 years (18 to 80 years). The most common sites were head and face and limbs (69.9% of all cases), and the trunk, digestive tract and reproductive system accounted for 11.0%, 8.1% and 8.5% respectively. The rare sites included mammary gland in 1 case, uterus in 2 cases, esophagus 3 For example, the entire group of patients received surgery and radiotherapy, chemotherapy, biotherapy, and biochemotherapy after admission. 111 patients had complete data, of whom 23 were treated with biological therapy (including TAK cells, IL-2, and IFN-α) after surgery; Thirty-four patients received biochemotherapy (single or multidrug chemotherapy combined with biological response modifiers); 48 patients received postoperative radiotherapy or chemotherapy. Chemotherapy drugs included DDP (100 mg/M2), CBP (350 mg/M2), and DTIC ( 125mg/M2×3)